EU Adopts Positive Opinion for Decision on Regulatory Approval of Quad
On 22 March 2013, Gilead announced in a press release that the EU has adopted a positive opinion for the once-daily, single tablet regimen Stribild (previously developed as Quad).
This indication is for use in treatment-naive and treatment-experienced patients.
Quad contains elvitegravir, an integrase inhibitor, and cobicistat, a PK booster, with tenofovir and FTC and was approved in the U.S. in August 2012.
The decision came from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) and such recommendations are usually followed. Full approval is therefore expected within three months.
European Commission Approves Stribild, a New Single Tablet Regimen for the Treatment of HIV-1 Infection
AIDS Healthcare Foundation Challenges Gilead Over AIDS Drug Price Gouging of U.S. Government Programs on Stribild
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)